Comparison of the effect of haloperidol and quetiapine in the prevention of delirium in patients with end-stage cancer candidates receiving palliative care at home
Phase 3
Recruiting
- Conditions
- Delirium.Delirium due to known physiological condition
- Registration Number
- IRCT20201205049612N1
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Diagnosis of any type of end-stage cancer in the patient by the oncologist (discontinuation of therapeutic treatment with a prognosis of less than 6 months)
Conscious consent of the patient or his family to participate in the study
Exclusion Criteria
Existence of major neurocagnetic disorder
Existence of delirium disorder according to DSM-V criteria by a psychiatric assistant and obtaining a score less than 5 in the ICDSC questionnaire
Any contraindications to the use of antipsychotic drugs
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Delirium prevention. Timepoint: 12 weeks after starting the drug. Method of measurement: ICDSC questionnaire.
- Secondary Outcome Measures
Name Time Method